A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy

• Egile Nagusiak: Wei Mu (Egilea), Xiaolu Long (Egilea), Haodong Cai (Egilea), Caixia Chen (Egilea), Guang Hu (Egilea), Yaoyao Lou (Egilea), Shugang Xing (Egilea), Di Wang (Egilea), Jue Wang (Egilea), Min Xiao (Egilea), Kun Wang (Egilea), Zhongyi Sun (Egilea), Chunrui Li (Egilea), Jianfeng Zhou (Egilea), Liting Chen (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Different from canonical drugs, CAR T-cells are "living drugs", which derived from patient's own blood. Studies of the pharmacokinetics of CAR T-cells could improve our understanding of their efficacy, safety, optimal dosage, and other characterizes. We previously reported a phase I s...